Biomerica
BMRA | NASDAQ
$1.32
-$0.04 (-2.94%)
At close: Nov 16, 2026, 4:00 PM ET
$1.32
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Biomerica Company Profile
Company profile explainedCompany Profile
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Key Executives
| Name | Position |
|---|---|
| Zackary S. Irani | Chief Executive Officer & Director |
| Allen C. Barbieri | Executive Vice-Chairman of the Board & Corporate Secretary |
| Gary Lu | Principal Accounting Officer |
| Lucy Liu | Director of Manufacturing & Technical Operations |
| Scott Madel | Chief Commercial Officer |
| Xiaoxuan Qu | Principal Financial Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | DEF 14A | Filing |
| Oct 15, 2026 | 10-Q | Quarterly Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 07, 2026 | EFFECT | Filing |
| Oct 07, 2026 | EFFECT | Filing |
| Sep 28, 2026 | 10-K/A | [Amend] Annual Report |
| Sep 24, 2026 | S-3 | Filing |
| Sep 24, 2026 | S-3 | Filing |
| Sep 10, 2026 | 3 | Filing |
| Sep 08, 2026 | 3 | Filing |
Biomerica
| Country | United States |
| IPO Date | Sep 7, 1984 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Zackary S. Irani |
Contact Details
17571 Von Karman Avenue Irvine,
California 92614 United States
Stock Details
| Ticker Symbol | BMRA |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0000073290 |
| CUSIP Number | 09061H406 |
| ISIN Number | US09061H4065 |
| SIC Code | 2835 |
Add to Watchlist
Select watchlists to add or remove BMRA